However, after treatment with anti-EGFR mAb, the vast majority of RAS wild-type colorectal cancer patients will develop disease progression within 3–12 months of treatment (Emburgh et al., 2014), which is mainly caused by the abnormal activation of the signaling cascade downstream of EGFR, including alterations of member genes in the RAS/RAF, PIK3CA/PTEN, and JAK/STAT pathway and activation of selective growth factor receptor bypass such as IGF1R, HER2, and MET. This evidence concerns the gene ERBB2 and colorectal cancer.